Relevance of Minor Neuropsychological Deficits in Patients With Subjective Cognitive Decline

Background and Objectives To determine the relevance of minor neuropsychological deficits (MNPD) in patients with subjective cognitive decline (SCD) with regard to CSF levels of Alzheimer disease (AD) biomarkers, cognitive decline, and clinical progression to mild cognitive impairment (MCI). Methods This study included patients with clinical SCD and SCD-free, healthy control (HC) participants with available baseline CSF and/or longitudinal cognitive data from the observational DZNE Longitudinal Cognitive Impairment and Dementia study. We defined MNPD as a performance of at least 0.5SD below the mean on a demographically adjusted total score derived from the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological assessment battery. We compared SCD patients with MNPD and those without MNPD with regard to CSF amyloid-β (Aβ)42/Aβ40, phosphorylated tau (p-tau181), total tau and Aβ42/p-tau181 levels, longitudinal cognitive composite trajectories, and risk of clinical progression to incident MCI (follow-up M ± SD: 40.6 ± 23.7 months). In addition, we explored group differences between SCD and HC in those without MNPD. Results In our sample (N = 672, mean age: 70.7 ± 5.9 years, 50% female), SCD patients with MNPD (n = 55, 12.5% of SCD group) showed significantly more abnormal CSF biomarker levels, increased cognitive decline, and a higher risk of progression to incident MCI (HR: 4.07, 95% CI 2.46–6.74) compared with SCD patients without MNPD (n = 384). MNPD had a positive predictive value of 57.0% (95% CI 38.5–75.4) and a negative predictive value of 86.0% (95% CI 81.9–90.1) for the progression of SCD to MCI within 3 years. SCD patients without MNPD showed increased cognitive decline and a higher risk of incident MCI compared with HC participants without MNPD (n = 215; HR: 4.09, 95% CI 2.07–8.09), while AD biomarker levels did not differ significantly between these groups. Discussion Our results suggest that MNPD are a risk factor for AD-related clinical progression in cognitively normal patients seeking medical counseling because of SCD. As such, the assessment of MNPD could be useful for individual clinical prediction and for AD risk stratification in clinical trials. However, SCD remains a risk factor for future cognitive decline even in the absence of MNPD.

[1]  W. Maier,et al.  Disentangling the relationship of subjective cognitive decline and depressive symptoms in the development of cognitive decline and dementia , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[2]  Yuehua Li,et al.  Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients , 2022, CNS neuroscience & therapeutics.

[3]  M. Bondi,et al.  Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint , 2022, Alzheimer's research & therapy.

[4]  Y. Hong,et al.  Subtle Cognitive Deficits Are Associated with Amyloid-β Positivity, but Not Severity of Self-Reported Decline: Results from the CoSCo Study , 2022, Dementia and Geriatric Cognitive Disorders.

[5]  W. M. van der Flier,et al.  Characteristics of subjective cognitive decline associated with amyloid positivity , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[6]  C. Jack,et al.  A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer's Disease Based on Cogstate One Card Learning Accuracy Performance. , 2021, Journal of Alzheimer's disease : JAD.

[7]  Sterling C. Johnson,et al.  Validity Evidence for the Research Category, “Cognitively Unimpaired – Declining,” as a Risk Marker for Mild Cognitive Impairment and Alzheimer’s Disease , 2021, Frontiers in Aging Neuroscience.

[8]  L. Schneider,et al.  Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group , 2021, The Lancet Neurology.

[9]  Eric E. Smith,et al.  Mild Behavioral Impairment and Subjective Cognitive Decline Predict Cognitive and Functional Decline , 2021, Journal of Alzheimer's disease : JAD.

[10]  L. Tan,et al.  Subtle cognitive impairment as a marker of Alzheimer's pathologies and clinical progression in cognitively normal individuals , 2021, Alzheimer's & dementia.

[11]  C. Jack,et al.  Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment. , 2020, Journal of Alzheimer's disease : JAD.

[12]  Keith A. Johnson,et al.  Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. , 2020, JAMA neurology.

[13]  M. Bondi,et al.  Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration , 2019, Neurology.

[14]  Keith A. Johnson,et al.  Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD , 2019, Alzheimer's & Dementia.

[15]  Keith A. Johnson,et al.  Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study , 2019, Alzheimer's & dementia.

[16]  W. M. van der Flier,et al.  Subjective cognitive decline and rates of incident Alzheimer’s disease and non-Alzheimer’s disease dementia , 2018, Alzheimer's & Dementia.

[17]  W. Jagust,et al.  Memory decline accompanies subthreshold amyloid accumulation , 2018, Neurology.

[18]  F. Jessen,et al.  Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer’s disease (DELCODE) , 2018, Alzheimer's Research & Therapy.

[19]  Sandra Weintraub,et al.  Objective features of subjective cognitive decline in a United States national database , 2017, Alzheimer's & Dementia.

[20]  R. Sperling,et al.  Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5 , 2017, Alzheimer's & dementia.

[21]  C. Jack,et al.  Memory, executive, and multi-domain subtle cognitive impairment: Clinical and biomarker finding , 2015, Alzheimer's & Dementia.

[22]  Benoit Liquet,et al.  Estimation of extended mixed models using latent classes and latent processes: the R package lcmm , 2015, 1503.00890.

[23]  Matthew L Senjem,et al.  Indicators of amyloid burden in a population-based study of cognitively normal elderly , 2012, Neurology.

[24]  A. Monsch,et al.  Early detection of Alzheimer’s disease with a total score of the German CERAD , 2010, Journal of the International Neuropsychological Society.

[25]  Alexandra Polchera,et al.  A Comparison of Operational Definitions for Mild Cognitive Impairment , 2022 .

[26]  H. Jacqmin-Gadda,et al.  American Journal of Epidemiology Practice of Epidemiology Misuse of the Linear Mixed Model When Evaluating Risk Factors of Cognitive Decline , 2022 .